Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis - 09/08/11
, Bruce Miller, MD b, Kenneth B. Gordon, MD c, Ivor Caro, MD d, Paul Kwon, MD d, Peter G. Compton, MA d, Craig L. Leonardi, MD efor the Efalizumab Study Group
Reprint requests: Kim A. Papp, MD, PhD, Probity Medical Research, 135 Union St E, Waterloo, Ontario N2J 1C4 Canada.Waterloo, Ontario, Canada; Portland, Oregon; Maywood, Illinois; South San Francisco, California; and St. Louis, Missouri
Abstract |
Background |
Efalizumab targets T cell–mediated steps important in psoriasis immunopathogenesis.
Objective |
We sought to evaluate the efficacy and safety of efalizumab retreatment in patients with moderate to severe plaque psoriasis.
Methods |
In this open-label, phase III study, 365 patients who received efalizumab therapy during an earlier clinical trial were retreated with 12 weeks of subcutaneous efalizumab (1 mg/kg/wk) 35 days or more after their last dose of efalizumab.
Results |
After 12 weeks of efalizumab retreatment, 56.9% of patients achieved 50% or more improvement from baseline Psoriasis Area and Severity Index (PASI) and 25.3% achieved at least 75% reduction in PASI score. The mean percentage PASI improvement from baseline was 51.2%. Overall, 76.1% of patients surveyed were “very satisfied” or “satisfied” with the efficacy of efalizumab. The safety profile of efalizumab retreatment was similar to that observed in patients receiving efalizumab for the first time.
Limitations |
Not all patients received sufficient exposure to efalizumab during their previous efalizumab clinical trial to allow for determination of their initial response to efalizumab. Of 365 patients enrolled in the study, 282 received at least 12 weeks of prior efalizumab therapy; of these patients, 208 (73.8%) achieved a PASI-50 response from their previous therapy.
Conclusion |
These results suggest that retreatment with efalizumab therapy is an efficacious option for patients who have previously discontinued treatment.
Le texte complet de cet article est disponible en PDF.Abbreviations used : HAHA, PASI, PASI-50, PASI-75, PGA, SC
Plan
| Supported by Genentech Inc and Serono International SA. Disclosures: Dr Miller has no conflict of interest to disclose. Dr Caro, Dr Kwon, and Mr Compton are stock shareholders and employees of Genentech Inc. Dr Gordon has received research support and honoraria from Genentech Inc. Dr Leonardi has received educational grant support from and served on the speakers bureau and advisory board for Genentech Inc. Dr Papp is a consultant, an investigator, and an advisory board member for Genentech Inc, Serono International SA, and Xoma, LLC; he is on the Serono International SA speakers bureau. Helix Medical Communications LLC was contracted by Genentech Inc and Serono International SA to provide editorial support for manuscript development. Presented in part as posters at the 12th Congress of the European Academy of Dermatology and Venereology; Florence, Italy; November 17-21, 2004; and the Meeting of the American Association of Dermatology; San Francisco, Calif; March 21-26, 2003. |
Vol 54 - N° 4S
P. S164-S170 - avril 2006 Retour au numéro
Article précédent
- Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial
- Alice B. Gottlieb, Tiffani Hamilton, Ivor Caro, Paul Kwon, Peter G. Compton, Craig L. Leonardi, for the Efalizumab Study Group
- Relapse, rebound, and psoriasis adverse events: An advisory group report
- Wayne Carey, Scott Glazer, Alice B. Gottlieb, Mark Lebwohl, Craig Leonardi, Alan Menter, Kim Papp, Amy Chen Rundle, Darryl Toth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?